Perceptive Advisors’s X4 Pharmaceuticals XFOR Stock Holding History

Perceptive Advisors’s Portfolio XFOR Stock Details XFOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$37M	Buy	7,933,491 +1,195,843	+18%	+$4.91M	0.56%	40
2026 Q1	$27.8M	Buy	6,737,648 +423,196	+7%	+$1.59M	0.54%	39
2025 Q4	$25.3M	Buy	+6,314,452	New	+$22.9M	0.45%	54
2024 Q4	–	Sell	-118,182	Closed	-$2.37M	–	123
2024 Q3	$2.37M	Hold	118,182	–	–	0.05%	91
2024 Q2	$2.06M	Hold	118,182	–	–	0.05%	94
2024 Q1	$4.93M	Hold	118,182	–	–	0.09%	87
2023 Q4	$2.97M	Hold	118,182	–	–	0.07%	84
2023 Q3	$3.86M	Hold	118,182	–	–	0.13%	74
2023 Q2	$6.88M	Sell	118,182 -33,333	-22%	-$1.71M	0.2%	71
2023 Q1	$3.95M	Buy	+151,515	New	+$4.44M	0.12%	79

Other funds holding XFOR

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

EAM

Empery Asset Management New York $86.5M AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Perceptive Advisors's XFOR Position: Q2 2026 in Review

Perceptive Advisors increased its X4 Pharmaceuticals (XFOR) stake by 18% in Q2 2026, buying an estimated $4.91M and bringing the position to 7,933,491 shares worth $37M. The position accounts for 0.56% of the portfolio, ranked #40.

Perceptive Advisors first reported a position in XFOR in Q1 2023 and has held it in 10 quarters since. 89 funds tracked by Wall St. Rank hold XFOR as of Q2 2026.

Perceptive Advisors held 7,933,491 shares of X4 Pharmaceuticals worth $37M as of Q2 2026.
Perceptive Advisors bought 1,195,843 X4 Pharmaceuticals shares in Q2 2026, an estimated $4.91M.
X4 Pharmaceuticals made up 0.56% of Perceptive Advisors's portfolio in Q2 2026, its #40 holding.
Perceptive Advisors first reported a position in X4 Pharmaceuticals in Q1 2023 and has held it in 10 quarters since.
89 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2026.

Based on Perceptive Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.